Targeting Soluble DPP-4 for Insulin Resistance: Origin Matters

J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1460-e1462. doi: 10.1210/clinem/dgaa902.

Authors

Lale Ozcan¹, Devram S Ghorpade², Ira Tabas^{1

3

4}

Affiliations

¹ Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
² Immuno-inflammation Laboratory, National Institute of Immunology, New Delhi, Delhi, India.
³ Department of Physiology and Cellular Biophysics, Columbia University Irving Medical Center, New York, NY, USA.
⁴ Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.

No abstract available

Keywords: DPP-4; insulin resistance; obesity; type 2 diabetes.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Dipeptidyl Peptidase 4
Dipeptidyl-Peptidase IV Inhibitors*
Humans
Insulin Resistance*

Substances

Dipeptidyl-Peptidase IV Inhibitors
Dipeptidyl Peptidase 4

Grants and funding

P01 HL087123/HL/NHLBI NIH HHS/United States